Everolimus is an oral analog (analog of rapamycin) used for the treatment of postmenopausal women with HR+, HER2− advanced breast cancer in combination with exemestane and after letrozole or anastrozole treatment failure. This evidence concerns the gene ERBB2 and breast cancer.